Actos Side Effects May Raise Bladder Cancer Risk: Study

Further evidence seems to suggest a possible link between side effects of Actos, a popular diabetes drug, and a potential increased risk of bladder cancer.

According to a study published in medical journal Diabetes Care, the risk of bladder cancer from Actos appears to be disproportionately higher than with other diabetes medications.

In September 2010, the FDA announced that it had launched an investigation into potential Actos bladder cancer side effects after data from an ongoing study by the drug’s manufacturer, Takeda Pharmaceuticals, suggested that users of the medication may have an increased risk of cancer from Actos the longer they took the medication.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

For this most recent study, Italian researchers looked at data collected by the U.S. regulators through the FDA’s Adverse Event Reporting System (AERS) and found that about one-fifth of all reports involving bladder cancer among diabetes drug users involved Actos. Although the study does not establish that there is a causal effect between Actos and bladder cancer, the rate among users of other diabetes drugs was significantly lower.

Researchers warned that they could not find any mechanism that would lead to Actos causing bladder cancer, and suggested that the findings could be tainted by “notoriety bias,” in which one report about a drug side effects sparks other reports.

Actos (pioglitazone) was approved by FDA to treat Type 2 Diabetes in July, 1999. It is Takeda Pharmaceuticals’ best-selling drug, with sales of $3.4 billion last year.

Sales have increased in recent years after a number of studies have suggested that Actos may be safer than its competitor, Avandia, which has been linked to an increased risk of heart attacks and deaths.

2 Comments

  • BrandiMay 29, 2011 at 5:07 pm

    I was on actos for about 6 months is that considered long term use? My doctor took me off in January 2011. I also took Lantus solopen for about 31/2 years and was taken off. I knew when I started the actos I had severe heart papulations and I felt my heart stop many times. Now that I've been off my side effects have gone away. How can something that suppose to be good for you make you worse than [Show More]I was on actos for about 6 months is that considered long term use? My doctor took me off in January 2011. I also took Lantus solopen for about 31/2 years and was taken off. I knew when I started the actos I had severe heart papulations and I felt my heart stop many times. Now that I've been off my side effects have gone away. How can something that suppose to be good for you make you worse than before.

  • Y.HMay 24, 2011 at 10:49 am

    since the marketing of Actos word wide and the huge number of patient exposures there is no sugestive clinical data of Bladder cancer increse. The question is the bladder cancer incidance increased after the long use of Actos?

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.